The predictors of the efficacy of pharmacological cardioversion with class III antiarrhythmic drug - nibentan in patients with persistent atrial fibrillation

被引：0
|
作者：
Bregvadze, I. [1 ]
Maykov, E. [2 ]
Sokolov, S. [2 ]
Golitsyn, S. [2 ]
Rozenshtraukh, L. [2 ]
Chazov, E. [2 ]
Pagava, Z. [1 ]
机构：
[1] Ctr Vasc & Heart Dis, Cardiol, Tbilisi, Georgia
[2] Cardiol Res & Prod Ctr, Clin Electrophysiol, Moscow, Russia
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6383
引用
收藏
页码：1374 / 1374
页数：1
相关论文
共 50 条
  • [21] Myocardial contractility after in Vitro treatment with class III antiarrhythmic drug Nibentan
    I. A. Latfullin
    R. F. Gaifullina
    R. K. Dzhordzhikiya
    R. R. Nigmatullina
    Bulletin of Experimental Biology and Medicine, 2006, 141 : 81 - 83
  • [22] Development of Drug Substances of the Original Class III Antiarrhythmic Drugs Nibentan and Niferidyl
    N. K. Davydova
    Pharmaceutical Chemistry Journal, 2019, 53 : 792 - 796
  • [23] Development of Drug Substances of the Original Class III Antiarrhythmic Drugs Nibentan and Niferidyl
    Davydova, N. K.
    PHARMACEUTICAL CHEMISTRY JOURNAL, 2019, 53 (09) : 792 - 796
  • [24] Clinical study of nibentan - New class III antiarrhythmic drug .3. Efficacy in patients with ventricular arrhythmias; Arrhythmogenic effects
    Merkulova, IN
    Tararak, AE
    Kotkin, KL
    Gilitsin, SP
    Rosenshtraukh, LV
    Ruda, MY
    Chazov, EI
    KARDIOLOGIYA, 1997, 37 (04) : 3 - 15
  • [25] ELECTROPHYSIOLOGIC DETERMINANTS OF PHARMACOLOGICAL CONVERSION OF HUMAN ATRIAL-FIBRILLATION AND FLUTTER - ENHANCED EFFICACY OF IBUTILIDE A NEW CLASS-III ANTIARRHYTHMIC DRUG
    STAMBLER, BS
    WOOD, MA
    BELZ, MK
    SPERRY, RE
    VANDERLUGT, JT
    ELLENBOGEN, KA
    CIRCULATION, 1993, 88 (04) : 445 - 445
  • [26] Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation
    Minami, T
    Isomoto, S
    Nakao, K
    Komiya, N
    Fukae, S
    Centurion, OA
    Yano, K
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2004, 27 (02): : 212 - 217
  • [27] Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect
    Yoshida, T
    Niwano, S
    Inuo, K
    Saito, J
    Kojima, J
    Ikeda-Murakami, K
    Hara, H
    Izumi, T
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2003, 26 (01): : 314 - 317
  • [28] Atrial function after cardioversion in patients with persistent atrial fibrillation
    Noda, K.
    Sunamura, S.
    Onodera, K.
    Tanita, A.
    Ogata, T.
    Takii, T.
    Namiuchi, S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [29] Efficacy and safety of antiarrhythmic drugs for pharmacological cardioversion of atrial fibrillation depending on gender: a subanalysis of CANT II Study
    Wybraniec, M.
    Maciag, A.
    Miskowiec, D.
    Balsam, P.
    Wojcik, M.
    Wrobel, W.
    Farkowski, M.
    Cwiek-Rebowska, E.
    Szolkiewicz, M.
    Bula, K.
    Krzowski, B.
    Kozinski, M.
    Kasprzak, J.
    Szwed, H.
    Mizia-Stec, K.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [30] Predictors of success and effect of biphasic energy on electrical cardioversion in patients with persistent atrial fibrillation
    Alegret, Josep M.
    Vinolas, Xavier
    Sagrista, Jaume
    Hernandez-Madrid, Antonio
    Perez, Luisa
    Sabate, Xavier
    Mont, Lluis
    Medina, Alfonso
    EUROPACE, 2007, 9 (10): : 942 - 946
12345